Advertisement
Advertisement
http://2015.eurothrombosis.eu

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH13-01-0042
Issue: 2014: 111/1 (Jan) pp. 1–189
Pages: 88-93

Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients

T.-F. Wang (1, 2), P. E. Milligan (2, 3), C. A. Wong (3), E. N. Deal (4), M. S. Thoelke (2), B. F. Gage (2)

(1) Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio, USA; (2) Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA; (3) Center for Clinical Excellence, BJC HealthCare, Saint Louis, Missouri, USA; (4) Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, Missouri, USA

Keywords

obesity, thromboprophylaxis, venous thromboembolism, obese inpatient

Summary

Obesity increases the risk for venous thromboembolism (VTE), but whether high-dose thromboprophylaxis is safe and effective in morbidly obese inpatients is unknown. It was the objective of this study to quantify the efficacy and safety of high-dose thromboprophylaxis with heparin or enoxaparin in inpatients with weight > 100 kilograms (kg) within the BJC HealthCare system. Ina retrospective cohort study, we analysed 9,241 inpatients with weight > 100 kg discharged from three hospitals in the BJC HealthCare system from 2010 through 2012. We compared the incidence of VTE in patients who received high-dose thromboprophylaxis (heparin 7,500 units three times daily or enoxaparin 40 mg twice daily) to those who received standard doses (heparin 5,000 units two or three times daily or enoxaparin 40 mg once daily). The primary efficacy outcome was hospital-acquired VTE identified by International Classification of Diseases (ICD)-9 diagnosis codes. The primary safety outcome was bleeding events identified by ICD-9 codes. Among the 3,928 morbidly obese inpatients (weight > 100 kg and body mass index [BMI] ≥ 40 kg/m²), high-dose thromboprophylaxis approximately halved the odds of symptomatic VTE (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.27–1.00; p = 0.050). The rate of VTE was 1.48% (35/2,369) in these morbidly obese inpatients who received standard doses of thromboprophylaxis, compared to 0.77% (12/1,559) in those who received high doses. High-dose thromboprophylaxis did not increase bleeding (OR 0.84, 95% CI 0.66–1.07, p = 0.15). Independent predictors of VTE were surgery, male sex, cancer, and BMI. In conclusion, high-dose thromboprophylaxis nearly halves the rate of VTE in morbidly obese inpatients.

You may also be interested in...

1.
Urs Kistler1, Inès Kramers-de Quervain2, Urs Munzinger3, Nils Kucher4

Thromb Haemost 2008 99 6: 1049-1052

http://dx.doi.org/10.1160/TH08-01-0019

2.
Rupert M. Bauersachs1, Joachim Dudenhausen2, Andree Faridi3, Thorsten Fischer4, Samson Fung5, Ulrich Geisen6, Job Harenberg7, Eberhard Herchenhan8, Franz Keller9, Bettina Kemkes-Matthes10, Helmut Schinzel11, Michael Spannagl12, Christian J. Thaler13, for the EThIG Investigators*

Thromb Haemost 2007 98 6: 1237-1245

http://dx.doi.org/10.1160/TH07-05-0329

3.
K. Kröger1, W. D. Paar2

Phlebologie 2006 35 6: 281-285